Mr. Cameron Groome reports

MICROBIX SCHEDULES RELEASE OF RESULTS FOR Q1 FISCAL 2024

Microbix Biosystems Inc. expects to file the financial statements and management disclosure and analysis for its first quarter of fiscal 2024 ended Dec. 31, 2023, prior to the start of trading on Feb. 14, 2024. Furthermore, at 10 a.m. ET on that day, Microbix intends to hold a webinar discussion of Q1 2024 results with its chief executive officer, chief financial officer and chief operating officer.

Investor and shareholders can participate in the webinar, hosted by Adelaide Capital, by registering on-line.

It will also be live streamed to YouTube.

Telephone participation in the webinar can be arranged by contacting Microbix or Adelaide Capital.

A replay of the webinar will also be made available on Adelaide Capital's YouTube channel.

About Microbix Biosystems Inc.

Microbix Biosystems creates proprietary biological products for human health, with over 100 skilled employees and annualized sales targeting $2-million per month. It makes a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs are sold to clinical lab accreditation organizations, diagnostics companies and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 and 13485 accredited, U.S. Food and Drug Administration registered, Australian Therapeutic Good Administration registered, and Health Canada establishment licensed, and provides CE marked products.

We seek Safe Harbor.